Ruterbusch, M., Pruner, K. B., Shehata, L. & Pepper, M. In Vivo CD4(+) T cell differentiation and function: revisiting the Th1/Th2 paradigm. Annu Rev. Immunol. 38, 705–725 (2020).
Sun, L. et al. T cells in health and disease. Signal Transduct. Target Ther. 8, 235 (2023).
Nakandakari-Higa, S. et al. Universal recording of immune cell interactions in vivo. Nature 627, 399–406 (2024).
Malyshkina, A., Brüggemann, A., Paschen, A. & Dittmer, U. Cytotoxic CD4(+) T cells in chronic viral infections and cancer. Front Immunol. 14, 1271236 (2023).
Wang, B., Hu, S., Fu, X. & Li, L. CD4(+) cytotoxic T lymphocytes in cancer immunity and immunotherapy. Adv. Biol. 7, e2200169 (2023).
Argyriou, A. et al. Single cell sequencing identifies clonally expanded synovial CD4(+) T(PH) cells expressing GPR56 in rheumatoid arthritis. Nat. Commun. 13, 4046 (2022).
Trzupek, D. et al. Single-cell multi-omics analysis reveals IFN-driven alterations in T lymphocytes and natural killer cells in systemic lupus erythematosus. Wellcome Open Res 6, 149 (2021).
Kitano, S. et al. Enhancement of tumor-reactive cytotoxic CD4+ T cell responses after ipilimumab treatment in four advanced melanoma patients. Cancer Immunol. Res 1, 235–244 (2013).
Sultan, H. et al. Neoantigen-specific cytotoxic Tr1 CD4 T cells suppress cancer immunotherapy. Nature 632, 182–191 (2024).
Lyu, M. et al. Dissecting the landscape of activated CMV-stimulated CD4+ T cells in humans by linking single-cell RNA-Seq with T-cell receptor sequencing. Front. Immunol. 12, 779961 (2021).
Sanchez-Martinez, A. et al. Cytotoxic CD4(+) T-cells during HIV infection: targets or weapons? J. Clin. Virol. 119, 17–23 (2019).
Broadley, I. et al. Expansions of cytotoxic CD4(+)CD28(-) T cells drive excess cardiovascular mortality in rheumatoid arthritis and other chronic inflammatory conditions and are triggered by CMV infection. Front Immunol. 8, 195 (2017).
Téo, F. H. et al. Characterization of CD4+CD28null T cells in patients with coronary artery disease and individuals with risk factors for atherosclerosis. Cell Immunol. 281, 11–19 (2013).
Dumitriu, I. E., Araguás, E. T., Baboonian, C. & Kaski, J. C. CD4+ CD28null T cells in coronary artery disease: when helpers become killers. Cardiovasc. Res. 81, 11–19 (2009).
Zhang, M. et al. Rapamycin improves Graves’ orbitopathy by suppressing CD4+ cytotoxic T lymphocytes. JCI Insight 8, e160377 (2023).
Bediaga, N. G. et al. Cytotoxicity-related gene expression and chromatin accessibility define a subset of CD4+ T cells that mark progression to type 1 diabetes. Diabetes 71, 566–577 (2022).
Feighery, C. & Stastny, P. HLA-D region-associated determinants serve as targets for human cell-mediated lysis. J. Exp. Med. 149, 485–494 (1979).
Fleischer, B. Acquisition of specific cytotoxic activity by human T4+ T lymphocytes in culture. Nature 308, 365–367 (1984).
Lukacher, A. E. et al. Expression of specific cytolytic activity by H-2I region-restricted, influenza virus-specific T lymphocyte clones. J. Exp. Med. 162, 171–187 (1985).
Maimone, M. M., Morrison, L. A., Braciale, V. L. & Braciale, T. J. Features of target cell lysis by class I and class II MHC-restricted cytolytic T lymphocytes. J. Immunol. 137, 3639–3643 (1986).
Chang, J. C., Zhang, L., Edgerton, T. L. & Kaplan, A. M. Heterogeneity in direct cytotoxic function of L3T4 T cells. TH1 clones express higher cytotoxic activity to antigen-presenting cells than TH2 clones. J. Immunol. 145, 409–416 (1990).
Lancki, D. W., Hsieh, C. S. & Fitch, F. W. Mechanisms of lysis by cytotoxic T lymphocyte clones. Lytic activity and gene expression in cloned antigen-specific CD4+ and CD8+ T lymphocytes. J. Immunol. 146, 3242–3249 (1991).
Yasukawa, M. et al. Granule exocytosis, and not the fas/fas ligand system, is the main pathway of cytotoxicity mediated by alloantigen-specific CD4(+) as well as CD8(+) cytotoxic T lymphocytes in humans. Blood 95, 2352–2355 (2000).
Hao, Y. et al. CTLA4 protects against maladaptive cytotoxicity during the differentiation of effector and follicular CD4(+) T cells. Cell Mol. Immunol. 20, 777–793 (2023).
Sujino, T. et al. Tissue adaptation of regulatory and intraepithelial CD4⁺ T cells controls gut inflammation. Science 352, 1581–1586 (2016).
Namekawa, T. et al. Killer cell activating receptors function as costimulatory molecules on CD4+CD28null T cells clonally expanded in rheumatoid arthritis. J. Immunol. 165, 1138–1145 (2000).
Wang, H. et al. TNF-α/IFN-γ profile of HBV-specific CD4 T cells is associated with liver damage and viral clearance in chronic HBV infection. J. Hepatol. 72, 45–56 (2020).
Torpey, D. J. 3rd, Lindsley, M. D. & Rinaldo, C. R. Jr. HLA-restricted lysis of herpes simplex virus-infected monocytes and macrophages mediated by CD4+ and CD8+ T lymphocytes. J. Immunol. 142, 1325–1332 (1989).
Suni, M. A. et al. CD4(+)CD8(dim) T lymphocytes exhibit enhanced cytokine expression, proliferation and cytotoxic activity in response to HCMV and HIV-1 antigens. Eur. J. Immunol. 31, 2512–2520 (2001).
Schmidt, D., Goronzy, J. J. & Weyand, C. M. CD4+ CD7– CD28– T cells are expanded in rheumatoid arthritis and are characterized by autoreactivity. J. Clin. Invest 97, 2027–2037 (1996).
Weyand, C. M. et al. Functional properties of CD4+ CD28– T cells in the aging immune system. Mech. Ageing Dev. 102, 131–147 (1998).
Liuzzo, G. et al. Perturbation of the T-cell repertoire in patients with unstable angina. Circulation 100, 2135–2139 (1999).
Xie, Y. et al. Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma. J. Exp. Med 207, 651–667 (2010).
Patil, V. S. et al. Precursors of human CD4+ cytotoxic T lymphocytes identified by single-cell transcriptome analysis. Sci. Immunol. 3, eaan8664 (2018).
Oja, A. E. et al. The transcription factor hobit identifies human cytotoxic CD4(+) T cells. Front Immunol. 8, 325 (2017).
Devarajan, P. et al. Cytotoxic CD4 development requires CD4 effectors to concurrently recognize local antigen and encounter type I IFN-induced IL-15. Cell Rep. 42, 113182 (2023).
Tanemoto, S. et al. Single-cell transcriptomics of human gut T cells identifies cytotoxic CD4(+)CD8A(+) T cells related to mouse CD4 cytotoxic T cells. Front Immunol. 13, 977117 (2022).
Liang, C. et al. Oligoclonal CD4(+)CXCR5(+) T cells with a cytotoxic phenotype appear in tonsils and blood. Commun. Biol. 7, 879 (2024).
Melenhorst, J. J. et al. Decade-long leukaemia remissions with persistence of CD4(+) CAR T cells. Nature 602, 503–509 (2022).
Snyder, M. R. et al. Formation of the killer Ig-like receptor repertoire on CD4+CD28null T cells. J. Immunol. 168, 3839–3846 (2002).
Zal, B. et al. Differential pathways govern CD4+ CD28– T cell proinflammatory and effector responses in patients with coronary artery disease. J. Immunol. 181, 5233–5241 (2008).
Sun, W., Zheng, L. & Huang, L. Role of unusual CD4+ CD28– T cells in acute coronary syndrome. Mol. Biol. Rep. 39, 3337–3342 (2012).
Wei, L., Xiang, Z. & Zou, Y. The role of NKG2D and its ligands in autoimmune diseases: New targets for immunotherapy. Int. J. Mol. Sci. 24, 17545 (2023).
Graham, C. M., Christensen, J. R. & Thomas, D. B. Differential induction of CD94 and NKG2 in CD4 helper T cells. A consequence of influenza virus infection and interferon-gamma? Immunology 121, 238–247 (2007).
Takeuchi, A. & Saito, T. CD4 CTL, a cytotoxic subset of CD4(+) T Cells, their differentiation and function. Front Immunol. 8, 194 (2017).
Liu, X. et al. Immune checkpoint HLA-E:CD94-NKG2A mediates evasion of circulating tumor cells from NK cell surveillance. Cancer Cell 41, 272–287.e279 (2023).
Freuchet, A. et al. Identification of human exT(reg) cells as CD16(+)CD56(+) cytotoxic CD4(+) T cells. Nat. Immunol. 24, 1748–1761 (2023).
Meyer, A., Parmar, P. J. & Shahrara, S. Significance of IL-7 and IL-7R in RA and autoimmunity. Autoimmun. Rev. 21, 103120 (2022).
Kim, S. et al. NKG2D-mediated cytotoxicity of CD4 cytotoxic T cells in multiple myeloma. Blood (2025).
Hashimoto, K. et al. Single-cell transcriptomics reveals expansion of cytotoxic CD4 T cells in supercentenarians. Proc. Natl. Acad. Sci. USA 116, 24242–24251 (2019).
Hoeks, C. et al. Treg-resistant cytotoxic CD4+ T cells dictate T helper cells in their vicinity: TH17 skewing and modulation of proliferation. Int. J. Mol. Sci. 22, 5660 (2021).
Cenerenti, M., Saillard, M., Romero, P. & Jandus, C. The era of Cytotoxic CD4 T cells. Front Immunol. 13, 867189 (2022).
Das, D. et al. Single cell mapping identifies expansion of Cytotoxic CD4 T cells in the atherosclerotic plaque of subjects with type 2 diabetes. J. Immunol. 210, 234.217–234.217 (2023).
Mucida, D. et al. Transcriptional reprogramming of mature CD4⁺ helper T cells generates distinct MHC class II-restricted cytotoxic T lymphocytes. Nat. Immunol. 14, 281–289 (2013).
Pawlik, A. et al. The increased number of CD4+CD28– T cells in patients after liver transplantation. Ann. Transpl. 8, 54–56 (2003).
Warrington, K. J., Vallejo, A. N., Weyand, C. M. & Goronzy, J. J. CD28 loss in senescent CD4+ T cells: reversal by interleukin-12 stimulation. Blood 101, 3543–3549 (2003).
Preglej, T. & Ellmeier, W. CD4(+) cytotoxic T cells—phenotype, function and transcriptional networks controlling their differentiation pathways. Immunol. Lett. 247, 27–42 (2022).
Takeuchi, A. et al. CRTAM determines the CD4+ cytotoxic T lymphocyte lineage. J. Exp. Med. 213, 123–138 (2016).
Redmond, W. L. Challenges and opportunities in the development of combination immunotherapy with OX40 agonists. Expert Opin. Biol. Ther. 23, 901–912 (2023).
Mittal, P. et al. An Immunotherapeutic CD137 agonist releases eomesodermin from ThPOK repression in CD4 T Cells. J. Immunol. 200, 1513–1526 (2018).
Kar, R. et al. Single-cell transcriptomic and T cell antigen receptor analysis of human cytomegalovirus (hCMV)-specific memory T cells reveals effectors and pre-effectors of CD8(+)- and CD4(+)-cytotoxic T cells. Immunology 172, 420–439 (2024).
Narmada, B. C. et al. Single-cell landscape of functionally cured chronic hepatitis B patients reveals activation of innate and altered CD4-CTL-driven adaptive immunity. J. Hepatol. 81, 42–61 (2024).
Herrera-De La Mata, S. et al. Cytotoxic CD4(+) tissue-resident memory T cells are associated with asthma severity. Medicines 4, 875–897.e878 (2023).
Kared, H. et al. CD57 in human natural killer cells and T-lymphocytes. Cancer Immunol. Immunother. 65, 441–452 (2016).
Lin, M. et al. Inflammatory dendritic cells restrain CD11b(+)CD4(+) CTLs via CD200R in human NSCLC. Cell Rep. 43, 113767 (2024).
Parsa, R. et al. Newly recruited intraepithelial Ly6A(+)CCR9(+)CD4(+) T cells protect against enteric viral infection. Immunity 55, 1234–1249.e1236 (2022).
Liu, H. et al. Neutralizing IL-8 potentiates immune checkpoint blockade efficacy for glioma. Cancer Cell 41, 693–710.e698 (2023).
Shi, S. et al. CXCR6 defines therapeutic subtypes of CD4(+) cytotoxic T cell lineage for adoptive cell transfer therapy in pediatric B cell acute lymphoblastic leukemia. Int. Immunopharmacol. 132, 111972 (2024).
Sallusto, F. et al. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401, 708–712 (1999).
Shah, K., Al-Haidari, A., Sun, J. & Kazi, J. U. T cell receptor (TCR) signaling in health and disease. Signal Transduct. Target Ther. 6, 412 (2021).
Spear, T. T., Evavold, B. D., Baker, B. M. & Nishimura, M. I. Understanding TCR affinity, antigen specificity, and cross-reactivity to improve TCR gene-modified T cells for cancer immunotherapy. Cancer Immunol. Immunother. 68, 1881–1889 (2019).
Legoux, F. et al. Characterization of the human CD4(+) T-cell repertoire specific for major histocompatibility class I-restricted antigens. Eur. J. Immunol. 43, 3244–3253 (2013).
Monks, C. R. et al. Three-dimensional segregation of supramolecular activation clusters in T cells. Nature 395, 82–86 (1998).
Finetti, F. & Baldari, C. T. The immunological synapse as a pharmacological target. Pharm. Res. 134, 118–133 (2018).
Vignaux, F. et al. TCR/CD3 coupling to Fas-based cytotoxicity. J. Exp. Med. 181, 781–786 (1995).
Mastio, J. et al. Higher incidence of B cell malignancies in primary immunodeficiencies: a combination of intrinsic genomic instability and exocytosis defects at the immunological synapse. Front. Immunol. 11, 581119 (2020).
Ueda, H., Morphew, M. K., McIntosh, J. R. & Davis, M. M. CD4+ T-cell synapses involve multiple distinct stages. Proc. Natl. Acad. Sci. USA 108, 17099–17104 (2011).
Beal, A. M. et al. Protein kinase C theta regulates stability of the peripheral adhesion ring junction and contributes to the sensitivity of target cell lysis by CTL. J. Immunol. 181, 4815–4824 (2008).
Dejaco, C. et al. NKG2D stimulated T-cell autoreactivity in giant cell arteritis and polymyalgia rheumatica. Ann. Rheum. Dis. 72, 1852–1859 (2013).
Cachot, A. et al. Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer. Sci. Adv. 7, eabe3348 (2021).
Dumitriu, I. E. et al. High levels of costimulatory receptors OX40 and 4-1BB characterize CD4+CD28null T cells in patients with acute coronary syndrome. Circ. Res. 110, 857–869 (2012).
White, J. T. et al. Virtual memory T cells develop and mediate bystander protective immunity in an IL-15-dependent manner. Nat. Commun. 7, 11291 (2016).
von Geldern, M. et al. TCR-independent cytokine stimulation induces non-MHC-restricted T cell activity and is negatively regulated by HLA class. I. Eur. J. Immunol. 36, 2347–2358 (2006).
Geginat, J., Sallusto, F. & Lanzavecchia, A. Cytokine-driven proliferation and differentiation of human naive, central memory, and effector memory CD4(+) T cells. J. Exp. Med. 194, 1711–1719 (2001).
Rokade, S., Damani, A. M., Oft, M. & Emmerich, J. IL-2 based cancer immunotherapies: an evolving paradigm. Front. Immunol. 15, 1433989 (2024).
Esser, M. T. et al. IL-2 induces Fas ligand/Fas (CD95L/CD95) cytotoxicity in CD8+ and CD4+ T lymphocyte clones. J. Immunol. 158, 5612–5618 (1997).
Xia, C. S. et al. IL-7 Promotes the expansion of circulating CD28- cytotoxic T lymphocytes in patients with IgG4-related disease via the JAK signaling. Front. Immunol. 13, 922307 (2022).
Wang, T. et al. Coordinated priming of NKG2D pathway by IL-15 enhanced functional properties of Cytotoxic CD4(+)CD28(-) T cells expanded in systemic lupus erythematosus. Inflammation 46, 1587–1601 (2023).
Taniuchi, I. CD4 helper and CD8 cytotoxic T cell differentiation. Annu. Rev. Immunol. 36, 579–601 (2018).
Luckey, M. A. et al. The transcription factor ThPOK suppresses Runx3 and imposes CD4(+) lineage fate by inducing the SOCS suppressors of cytokine signaling. Nat. Immunol. 15, 638–645 (2014).
Gao, Y. et al. NuRD complex recruitment to Thpok mediates CD4(+) T cell lineage differentiation. Sci. Immunol. 7, eabn5917 (2022).
Setoguchi, R., Taniuchi, I. & Bevan, M. J. ThPOK derepression is required for robust CD8 T cell responses to viral infection. J. Immunol. 183, 4467–4474 (2009).
Jenkinson, S. R. et al. Expression of the transcription factor cKrox in peripheral CD8 T cells reveals substantial postthymic plasticity in CD4-CD8 lineage differentiation. J. Exp. Med. 204, 267–272 (2007).
Cruz-Guilloty, F. et al. Runx3 and T-box proteins cooperate to establish the transcriptional program of effector CTLs. J. Exp. Med. 206, 51–59 (2009).
Wu, J. et al. The expanding Pandora’s toolbox of CD8(+)T cell: from transcriptional control to metabolic firing. J. Transl. Med. 21, 905 (2023).
Song, X. et al. Gut microbial fatty acid isomerization modulates intraepithelial T cells. Nature 619, 837–843 (2023).
Reis, B. S. et al. Mutual expression of the transcription factors Runx3 and ThPOK regulates intestinal CD4⁺ T cell immunity. Nat. Immunol. 14, 271–280 (2013).
Serroukh, Y. et al. The transcription factors Runx3 and ThPOK cross-regulate acquisition of cytotoxic function by human Th1 lymphocytes. Elife 7, e30496 (2018).
Knudson, C. J. et al. Mechanisms of antiviral cytotoxic CD4 T cell differentiation. J. Virol. 95, e0056621 (2021).
Eshima, K., Misawa, K., Ohashi, C. & Iwabuchi, K. Role of T-bet, the master regulator of Th1 cells, in the cytotoxicity of murine CD4(+) T cells. Microbiol. Immunol. 62, 348–356 (2018).
Hertweck, A. et al. T-bet activates Th1 genes through mediator and the super elongation complex. Cell Rep. 15, 2756–2770 (2016).
Śledzińska, A. et al. Regulatory T cells restrain interleukin-2- and Blimp-1-dependent acquisition of cytotoxic function by CD4(+) T cells. Immunity 52, 151–166.e156 (2020).
Brown, D. M. et al. IL-2 and antigen dose differentially regulate perforin- and FasL-mediated cytolytic activity in antigen-specific CD4+ T cells. Cell Immunol. 257, 69–79 (2009).
Hua, L. et al. Cytokine-dependent induction of CD4+ T cells with cytotoxic potential during influenza virus infection. J. Virol. 87, 11884–11893 (2013).
Djuretic, I. M. et al. Transcription factors T-bet and Runx3 cooperate to activate Ifng and silence Il4 in T helper type 1 cells. Nat. Immunol. 8, 145–153 (2007).
Eshima, K. et al. Ectopic expression of a T-box transcription factor, eomesodermin, renders CD4(+) Th cells cytotoxic by activating both perforin- and FasL-pathways. Immunol. Lett. 144, 7–15 (2012).
Thelen, B. et al. Eomes is sufficient to regulate IL-10 expression and cytotoxic effector molecules in murine CD4(+) T cells. Front. Immunol. 14, 1058267 (2023).
Raveney, B. J. E. et al. Involvement of cytotoxic Eomes-expressing CD4+ T cells in secondary progressive multiple sclerosis. Proc. Natl. Acad. Sci. USA. 118, e2021818118 (2021).
Gong, D. & Malek, T. R. Cytokine-dependent Blimp-1 expression in activated T cells inhibits IL-2 production. J. Immunol. 178, 242–252 (2007).
Peng, S. et al. CTLs heterogeneity and plasticity: implications for cancer immunotherapy. Mol. Cancer 23, 58 (2024).
Fu, S. H. et al. New insights into Blimp-1 in T lymphocytes: a divergent regulator of cell destiny and effector function. J. Biomed. Sci. 24, 49 (2017).
Jones, D. M., Read, K. A. & Oestreich, K. J. Dynamic roles for IL-2-STAT5 signaling in effector and regulatory CD4(+) T cell populations. J. Immunol. 205, 1721–1730 (2020).
Donnarumma, T. et al. Opposing development of cytotoxic and follicular helper CD4 T cells controlled by the TCF-1-Bcl6 nexus. Cell Rep. 17, 1571–1583 (2016).
Arase, N. et al. Heterotypic interaction of CRTAM with Necl2 induces cell adhesion on activated NK cells and CD8+ T cells. Int. Immunol. 17, 1227–1237 (2005).
Valle-Rios, R. et al. Characterization of CRTAM gene promoter: AP-1 transcription factor control its expression in human T CD8 lymphocytes. Mol. Immunol. 46, 3379–3387 (2009).
Rojas-Marquez, C., Valle-Rios, R., Lopez-Bayghen, E. & Ortiz-Navarrete, V. CRTAM is negatively regulated by ZEB1 in T cells. Mol. Immunol. 66, 290–298 (2015).
Yeh, J. H., Sidhu, S. S. & Chan, A. C. Regulation of a late phase of T cell polarity and effector functions by Crtam. Cell 132, 846–859 (2008).
Hofland, T. et al. CD4(+) T cell memory is impaired by species-specific cytotoxic differentiation, but not by TCF-1 loss. Front. Immunol. 14, 1168125 (2023).
Bossio, S. N. et al. CD39(+) conventional CD4(+) T cells with exhaustion traits and cytotoxic potential infiltrate tumors and expand upon CTLA-4 blockade. Oncoimmunology 12, 2246319 (2023).
Read, K. A. et al. Aiolos represses CD4(+) T cell cytotoxic programming via reciprocal regulation of T(FH) transcription factors and IL-2 sensitivity. Nat. Commun. 14, 1652 (2023).
Preglej, T. et al. Histone deacetylases 1 and 2 restrain CD4+ cytotoxic T lymphocyte differentiation. JCI Insight 5, e133393 (2020).
Barbosa, C. D. et al. Cytotoxic CD4(+) T cells driven by T-cell intrinsic IL-18R/MyD88 signaling predominantly infiltrate Trypanosoma cruzi-infected hearts. Elife 11, (2022).
Yang, Z. et al. Restoring oxidant signaling suppresses proarthritogenic T cell effector functions in rheumatoid arthritis. Sci. Transl. Med. 8, 331ra38 (2016).
Li, C., Lanasa, D. & Park, J. H. Pathways and mechanisms of CD4(+)CD8αα(+) intraepithelial T cell development. Trends Immunol. 45, 288–302 (2024).
Touch, S. et al. Human CD4+CD8α+ Tregs induced by Faecalibacterium prausnitzii protect against intestinal inflammation. JCI Insight 7, e154722 (2022).
Grakoui, A. et al. The immunological synapse: a molecular machine controlling T cell activation. Science 285, 221–227 (1999).
de Saint Basile, G., Ménasché, G. & Fischer, A. Molecular mechanisms of biogenesis and exocytosis of cytotoxic granules. Nat. Rev. Immunol. 10, 568–579 (2010).
Voskoboinik, I., Smyth, M. J. & Trapani, J. A. Perforin-mediated target-cell death and immune homeostasis. Nat. Rev. Immunol. 6, 940–952 (2006).
Hay, Z. L. Z. & Slansky, J. E. Granzymes: the molecular executors of immune-mediated cytotoxicity. Int. J. Mol. Sci. 23, 1833 (2022).
Voskoboinik, I., Whisstock, J. C. & Trapani, J. A. Perforin and granzymes: function, dysfunction and human pathology. Nat. Rev. Immunol. 15, 388–400 (2015).
Noshadi, N. et al. Impaired CD4+ cytotoxic T lymphocyte activity in polyomavirus BK-infected kidney transplant recipients. Iran. J. Allergy Asthma Immunol. 22, 379–389 (2023).
Fang, M. et al. Perforin-dependent CD4+ T-cell cytotoxicity contributes to control a murine poxvirus infection. Proc. Natl. Acad. Sci. USA 109, 9983–9988 (2012).
Ye, W., Young, J. D. & Liu, C. C. Interleukin-15 induces the expression of mRNAs of cytolytic mediators and augments cytotoxic activities in primary murine lymphocytes. Cell Immunol. 174, 54–62 (1996).
Chen, Z. et al. VEGF-A enhances the cytotoxic function of CD4(+) cytotoxic T cells via the VEGF-receptor 1/VEGF-receptor 2/AKT/mTOR pathway. J. Transl. Med. 21, 74 (2023).
Niiya, H. et al. Differential regulation of perforin expression in human CD4+ and CD8+ cytotoxic T lymphocytes. Exp. Hematol. 33, 811–818 (2005).
Lin, L. et al. Granzyme B secretion by human memory CD4 T cells is less strictly regulated compared to memory CD8 T cells. BMC Immunol. 15, 36 (2014).
Haymour, L., Jean, M., Smulski, C. & Legembre, P. CD95 (Fas) and CD95L (FasL)-mediated non-canonical signaling pathways. Biochim. Biophys. Acta Rev. Cancer 1878, 189004 (2023).
Juno, J. A. et al. Cytotoxic CD4 T cells-friend or foe during viral infection? Front. Immunol. 8, 19 (2017).
Oh, Y. T. & Sun, S. Y. Regulation of cancer metastasis by TRAIL/death receptor signaling. Biomolecules. 11, 499 (2021).
Kotov, D. I., Kotov, J. A., Goldberg, M. F. & Jenkins, M. K. Many Th cell subsets have Fas ligand-dependent cytotoxic potential. J. Immunol. 200, 2004–2012 (2018).
Akhmetzyanova, I. et al. CD137 Agonist therapy can reprogram regulatory T cells into cytotoxic CD4+ T cells with antitumor activity. J. Immunol. 196, 484–492 (2016).
Faber, L. M. et al. Generation of CD4+ cytotoxic T-lymphocyte clones from a patient with severe graft-versus-host disease after allogeneic bone marrow transplantation: implications for graft-versus-leukemia reactivity. Blood 86, 2821–2828 (1995).
Saigusa, R., Winkels, H. & Ley, K. T cell subsets and functions in atherosclerosis. Nat. Rev. Cardiol. 17, 387–401 (2020).
Komocsi, A. et al. Peripheral blood and granuloma CD4(+)CD28(-) T cells are a major source of interferon-gamma and tumor necrosis factor-alpha in Wegener’s granulomatosis. Am. J. Pathol. 160, 1717–1724 (2002).
Cruz-Adalia, A. et al. Conventional CD4(+) T cells present bacterial antigens to induce cytotoxic and memory CD8(+) T cell responses. Nat. Commun. 8, 1591 (2017).
Wang, Z., Chimenti, M. S., Strouse, C. & Weiner, G. J. T cells, particularly activated CD4(+) cells, maintain anti-CD20-mediated NK cell viability and antibody dependent cellular cytotoxicity. Cancer Immunol. Immunother. 71, 237–249 (2022).
Bogen, B., Fauskanger, M., Haabeth, O. A. & Tveita, A. CD4(+) T cells indirectly kill tumor cells via induction of cytotoxic macrophages in mouse models. Cancer Immunol. Immunother. 68, 1865–1873 (2019).
Thewissen, M. et al. CD4+CD28null T cells in autoimmune disease: pathogenic features and decreased susceptibility to immunoregulation. J. Immunol. 179, 6514–6523 (2007).
Kovalcsik, E. et al. Proteasome-mediated reduction in proapoptotic molecule Bim renders CD4⁺CD28null T cells resistant to apoptosis in acute coronary syndrome. Circulation 131, 709–720 (2015).
Tiriveedhi, V. et al. Mammaglobin-A cDNA vaccination of breast cancer patients induces antigen-specific cytotoxic CD4+ICOShi T cells. Breast Cancer Res. Treat. 138, 109–118 (2013).
Appay, V. et al. Characterization of CD4(+) CTLs ex vivo. J. Immunol. 168, 5954–5958 (2002).
Manzke, N. et al. CD4+ T cells develop antiretroviral cytotoxic activity in the absence of regulatory T cells and CD8+ T cells. J. Virol. 87, 6306–6313 (2013).
Morishita, Y., Sao, H., Hansen, J. A. & Martin, P. J. A distinct subset of human CD4+ cells with a limited alloreactive T cell receptor repertoire. J. Immunol. 143, 2783–2789 (1989).
Alonso-Arias, R. et al. NKG2D expression in CD4+ T lymphocytes as a marker of senescence in the aged immune system. Age 33, 591–605 (2011).
Winford, E. et al. Terminally differentiated effector memory T cells associate with cognitive and AD-related biomarkers in an aging-based community cohort. Immun. Ageing 21, 36 (2024).
Hasegawa, T. et al. Cytotoxic CD4(+) T cells eliminate senescent cells by targeting cytomegalovirus antigen. Cell 186, 1417–1431.e1420 (2023).
Jain, A., Sturmlechner, I., Weyand, C. M. & Goronzy, J. J. Heterogeneity of memory T cells in aging. Front. Immunol. 14, 1250916 (2023).
Swanton, C. et al. Embracing cancer complexity: hallmarks of systemic disease. Cell 187, 1589–1616 (2024).
Liu, G., Rui, W., Zhao, X. & Lin, X. Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment. Cell Mol. Immunol. 18, 1085–1095 (2021).
de Visser, K. E. & Joyce, J. A. The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth. Cancer Cell 41, 374–403 (2023).
Chow, M. T., Möller, A. & Smyth, M. J. Inflammation and immune surveillance in cancer. Semin. Cancer Biol. 22, 23–32 (2012).
Dunn, G. P. et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3, 991–998 (2002).
Nishimura, T. et al. Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J. Exp. Med. 190, 617–627 (1999).
Perez-Diez, A. et al. CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 109, 5346–5354 (2007).
Hunder, N. N. et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N. Engl. J. Med. 358, 2698–2703 (2008).
Quezada, S. A. et al. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J. Exp. Med. 207, 637–650 (2010).
Guo, X. et al. Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing. Nat. Med. 24, 978–985 (2018).
Zhang, L. et al. Lineage tracking reveals dynamic relationships of T cells in colorectal cancer. Nature 564, 268–272 (2018).
Oh, D. Y. et al. Intratumoral CD4(+) T cells mediate anti-tumor cytotoxicity in human bladder cancer. Cell 181, 1612–1625.e1613 (2020).
Chen, H. et al. Expansion of CD4+ cytotoxic T lymphocytes with specific gene expression patterns may contribute to suppression of tumor immunity in oral squamous cell carcinoma: single-cell analysis and in vitro experiments. Front. Immunol. 14, 1305783 (2023).
Zhang, Y. et al. Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer. Cancer Cell 39, 1578–1593.e1578 (2021).
Oh, D. Y. & Fong, L. Cytotoxic CD4(+) T cells in cancer: expanding the immune effector toolbox. Immunity 54, 2701–2711 (2021).
Chen, X. et al. A membrane-associated MHC-I inhibitory axis for cancer immune evasion. Cell 186, 3903–3920.e3921 (2023).
Hu, J. et al. Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing. Genome Med. 15, 14 (2023).
Liu, C. et al. Single-cell RNA-sequencing reveals radiochemotherapy-induced innate immune activation and MHC-II upregulation in cervical cancer. Signal Transduct. Target. Ther. 8, 44 (2023).
Lhuillier, C. et al. Radiotherapy-exposed CD8+ and CD4+ neoantigens enhance tumor control. J. Clin. Investig. 131, e138740 (2021).
Alspach, E. et al. MHC-II neoantigens shape tumour immunity and response to immunotherapy. Nature 574, 696–701 (2019).
Kim, J. Y. et al. MHC II immunogenicity shapes the neoepitope landscape in human tumors. Nat. Genet. 55, 221–231 (2023).
Bagot, M. et al. Isolation of tumor-specific cytotoxic CD4+ and CD4+CD8dim+ T-cell clones infiltrating a cutaneous T-cell lymphoma. Blood 91, 4331–4341 (1998).
Xu, Z. et al. TAGAP expression influences CD4+ T cell differentiation, immune infiltration, and cytotoxicity in LUAD through the STAT pathway: implications for immunotherapy. Front. Immunol. 14, 1224340 (2023).
Zhang, J., Scordi, I., Smyth, M. J. & Lichtenheld, M. G. Interleukin 2 receptor signaling regulates the perforin gene through signal transducer and activator of transcription (Stat)5 activation of two enhancers. J. Exp. Med. 190, 1297–1308 (1999).
Göschl, L. et al. A T cell-specific deletion of HDAC1 protects against experimental autoimmune encephalomyelitis. J. Autoimmun. 86, 51–61 (2018).
Lin, Y. C. et al. Murine cytotoxic CD4+ T cells in the tumor microenvironment are at a hyper-maturation stage of Th1 CD4+ T cells sustained by IL-12. Int. Immunol. 35, 387–400 (2023).
Wang, B. et al. Targeting PD-1 and CD85j can restore intratumoral CD4+ GzmB+ T-cell functions to combat MHC-II-expressing tumors. J. Immunother. Cancer. 13, e010890 (2025).
Sanderson, N. S. et al. Cytotoxic immunological synapses do not restrict the action of interferon-γ to antigenic target cells. Proc. Natl. Acad. Sci. USA 109, 7835–7840 (2012).
Kammertoens, T. et al. Tumour ischaemia by interferon-γ resembles physiological blood vessel regression. Nature 545, 98–102 (2017).
Braumüller, H. et al. T-helper-1-cell cytokines drive cancer into senescence. Nature 494, 361–365 (2013).
Thibaut, R. et al. Bystander IFN-γ activity promotes widespread and sustained cytokine signaling altering the tumor microenvironment. Nat. Cancer 1, 302–314 (2020).
de Miguel, D. et al. Inflammatory cell death induced by cytotoxic lymphocytes: a dangerous but necessary liaison. FEBS j. 289, 4398–4415 (2022).
Zhou, W. et al. Stem-like progenitor and terminally differentiated T(FH)-like CD4(+) T cell exhaustion in the tumor microenvironment. Cell Rep. 43, 113797 (2024).
Fusagawa, M. et al. Identification and phenotypic characterization of neoantigen-specific cytotoxic CD4+ T cells in endometrial cancer. Cancer Immunol. Res. 13, 171–184 (2025).
Bonnal, R. J. P. et al. Clonally expanded EOMES(+) Tr1-like cells in primary and metastatic tumors are associated with disease progression. Nat. Immunol. 22, 735–745 (2021).
Qi, J. et al. Analysis of immune landscape reveals prognostic significance of cytotoxic CD4(+) T cells in the central region of pMMR CRC. Front Oncol. 11, 724232 (2021).
Veatch, J. R. et al. Neoantigen-specific CD4(+) T cells in human melanoma have diverse differentiation states and correlate with CD8(+) T cell, macrophage, and B cell function. Cancer Cell 40, 393–409.e399 (2022).
Ouyang, W. et al. Synergistic role of activated CD4(+) memory T cells and CXCL13 in augmenting cancer immunotherapy efficacy. Heliyon 10, e27151 (2024).
Gu-Trantien, C. et al. CD4⁺ follicular helper T cell infiltration predicts breast cancer survival. J. Clin. Investig. 123, 2873–2892 (2013).
Sasidharan Nair, V. et al. Differential gene expression of tumor-infiltrating CD4(+) T cells in advanced versus early stage colorectal cancer and identification of a gene signature of poor prognosis. Oncoimmunology 9, 1825178 (2020).
Liu, Q. et al. Tumor-specific CD4(+) T cells restrain established metastatic melanoma by developing into cytotoxic CD4(-) T Cells. Front. Immunol. 13, 875718 (2022).
Germano, G. et al. CD4 T cell-dependent rejection of beta-2 microglobulin null mismatch repair-deficient tumors. Cancer Discov. 11, 1844–1859 (2021).
Draghi, A. et al. Uncoupling CD4+ TIL-mediated tumor killing from JAK-signaling in melanoma. Clin. Cancer Res. 29, 3937–3947 (2023).
Zhang, N. et al. Global burden of hematologic malignancies and evolution patterns over the past 30 years. Blood Cancer J. 13, 82 (2023).
Zhao, A. et al. Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies. Signal Transduct. Target. Ther. 8, 71 (2023).
Mumme, H. et al. Single-cell analysis reveals altered tumor microenvironments of relapse- and remission-associated pediatric acute myeloid leukemia. Nat. Commun. 14, 6209 (2023).
Tada, K. et al. Prognostic significance of HLA class I and II expression in patients with diffuse large B cell lymphoma treated with standard chemoimmunotherapy. Cancer Immunol. Immunother. 65, 1213–1222 (2016).
Brown, P. J. et al. FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas. Leukemia 30, 605–616 (2016).
Autio, M. et al. Immune cell constitution in the tumor microenvironment predicts the outcome in diffuse large B-cell lymphoma. Haematologica 106, 718–729 (2021).
Zhang, X. et al. Characterization of CD4(+) T cell-mediated cytotoxicity in patients with multiple myeloma. Cell Immunol. 327, 62–67 (2018).
Cieniewicz, B. et al. Engineered type 1 regulatory T cells designed for clinical use kill primary pediatric acute myeloid leukemia cells. Haematologica 106, 2588–2597 (2021).
Steger, B. et al. CD4(+)and CD8(+)T-cell reactions against leukemia-associated- or minor-histocompatibility-antigens in AML-patients after allogeneic SCT. Immunobiology 219, 247–260 (2014).
Nagasaki, J. et al. The critical role of CD4+ T cells in PD-1 blockade against MHC-II-expressing tumors such as classic Hodgkin lymphoma. Blood Adv. 4, 4069–4082 (2020).
Chinnasamy, D. et al. Generation of anti-tumor CD4+ T helper cells using genetically-engineered dendritic cells expressing leukemia-associated antigens. Blood 122, 2027–2027 (2013).
Kryukov, F. et al. In vitro activation of cytotoxic T-lymphocytes by hTERT-pulsed dendritic cells. J. Immunotoxicol. 6, 243–248 (2009).
Toubert, A. NKG2D and ligands: a two-edged sword in response to stress? Eur. J. Immunol. 1, S282 (2009).
Locafaro, G. et al. IL-10-Engineered human CD4(+) Tr1 cells eliminate myeloid leukemia in an HLA class I-dependent mechanism. Mol. Ther. 25, 2254–2269 (2017).
Porakishvili, N. et al. Cytotoxic CD4+ T cells in patients with B cell chronic lymphocytic leukemia kill via a perforin-mediated pathway. Haematologica 89, 435–443 (2004).
Ho, J. et al. Targeting MDM2 enhances antileukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1/2 upregulation. Blood 140, 1167–1181 (2022).
Kinsella, F. A. M., Maroto, M. A. L., Loke, J. & Craddock, C. Strategies to reduce relapse risk in patients undergoing allogeneic stem cell transplantation for acute myeloid leukaemia. Br. J. Haematol. 204, 2173–2183 (2024).
Zheng, H. et al. Effector memory CD4+ T cells mediate graft-versus-leukemia without inducing graft-versus-host disease. Blood 111, 2476–2484 (2008).
Matsushita, M. et al. Possible involvement of allogeneic antigens recognised by donor-derived CD4 cytotoxic T cells in selective GVL effects after stem cell transplantation of patients with haematological malignancy. Br. J. Haematol. 132, 56–65 (2006).
Roessner, P. M. et al. EOMES and IL-10 regulate antitumor activity of T regulatory type 1 CD4(+) T cells in chronic lymphocytic leukemia. Leukemia 35, 2311–2324 (2021).
Minnie, S. A. et al. The IL-2/IL-15 mimetic NL-201 prevents myeloma relapse after ASCT by expanding highly cytolytic T cells in the bone marrow that are resistant to exhaustion. Blood 138, 1609–1609 (2021).
Haque, A., Radwan, F. F. Y., Hossain, A. & God, J. M. Dual roles for ganoderic acid A in inducing apoptosis and enhancing HLA class II presentation in leukemia and lymphoma cells. Cancer Res. 72, 5641 (2012).
Drokov, M. et al. High expression of granzyme B in conventional CD4+ T cells is associated with increased relapses after allogeneic stem cells transplantation in patients with hematological malignancies. Transpl. Immunol. 65, 101295 (2021).
Drokov, M. Y. et al. Granzyme B expression in conventional CD4+ T-cells is strongly associated with increased relapse rate during first 6 months after Allo-HSCT. Blood 130, 1990–1990 (2017).
Venkatesh, H., Tracy, S. I. & Farrar, M. A. Cytotoxic CD4 T cells in the mucosa and in cancer. Front. Immunol. 14, 1233261 (2023).
Tracy, S. I. et al. Combining nilotinib and PD-L1 blockade reverses CD4+ T-cell dysfunction and prevents relapse in acute B-cell leukemia. Blood 140, 335–348 (2022).
Castillo, P. A. et al. Graft versus leukemia response without graft versus host disease elicited by adoptively transferred multivirus-specific T-cells. Blood 124, 2439–2439 (2014).
Agarwal, S. et al. In Vivo Generation of CAR T cells selectively in human CD4(+) lymphocytes. Mol. Ther. 28, 1783–1794 (2020).
Liadi, I. et al. Defining potency of CAR(+) T cells: fast and furious or slow and steady. Oncoimmunology 8, e1051298 (2019).
Ledergor, G. et al. CD4+ CAR T-cell exhaustion associated with early relapse of multiple myeloma after BCMA CAR T-cell therapy. Blood Adv. 8, 3562–3575 (2024).
Yuan, S. et al. Translatomic profiling reveals novel self-restricting virus-host interactions during HBV infection. J. Hepatol. 75, 74–85 (2021).
Seto, W. K., Lo, Y. R., Pawlotsky, J. M. & Yuen, M. F. Chronic hepatitis B virus infection. Lancet 392, 2313–2324 (2018).
Odenwald, M. A. & Paul, S. Viral hepatitis: past, present, and future. World J. Gastroenterol. 28, 1405–1429 (2022).
Zhang, C. et al. Single-cell RNA sequencing reveals intrahepatic and peripheral immune characteristics related to disease phases in HBV-infected patients. Gut 72, 153–167 (2023).
Khan, M. N. et al. Tumor-associated macrophages and CD8+ T cells: dual players in the pathogenesis of HBV-related HCC. Front Immunol. 15, 1472430 (2024).
Adugna, A. Antigen recognition and immune response to acute and chronic hepatitis B virus infection. J. Inflamm. Res 16, 2159–2166 (2023).
Herkel, J. et al. MHC class II-expressing hepatocytes function as antigen-presenting cells and activate specific CD4 T lymphocyutes. Hepatology 37, 1079–1085 (2003).
Yan, Z. H. et al. Relationship between HLA-DR gene polymorphisms and outcomes of hepatitis B viral infections: a meta-analysis. World J. Gastroenterol. 18, 3119–3128 (2012).
Tamori, A. & Kawada, N. HLA class II associated with outcomes of hepatitis B and C infections. World J. Gastroenterol. 19, 5395–5401 (2013).
Dezhbord, M. et al. Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction. Clin. Mol. Hepatol. 30, 539–560 (2024).
He, W. et al. IL-26 modulates T cell function in autoimmune hepatitis. J. Dig. Dis. 24, 231–242 (2023).
Aghayev, T. et al. IL27 Signaling serves as an immunologic checkpoint for innate cytotoxic cells to promote hepatocellular carcinoma. Cancer Discov. 12, 1960–1983 (2022).
Yu, X. et al. BTLA contributes to acute-on-chronic liver failure infection and mortality through CD4(+) T-cell exhaustion. Nat. Commun. 15, 1835 (2024).
Khanam, A., Ghosh, A., Chua, J. V. & Kottilil, S. Blockade of CCR4 breaks immune tolerance in chronic hepatitis B patients by modulating regulatory pathways. J. Transl. Med. 21, 271 (2023).
Aslan, N. et al. Cytotoxic CD4 T cells in viral hepatitis. J. Viral Hepat. 13, 505–514 (2006).
Jang, E. J. et al. Identification of cytotoxic CD4(+) population among CD69(-) liver-infiltrating T-cells. Gut Liver 18, 106 (2024).
Thimme, R. et al. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J. Virol. 77, 68–76 (2003).
Poynard, T. et al. Fibrosis in patients with chronic hepatitis C: detection and significance. Semin. Liver Dis. 20, 47–55 (2000).
Phillips, S. et al. CD8(+) T cell control of hepatitis B virus replication: direct comparison between cytolytic and noncytolytic functions. J. Immunol. 184, 287–295 (2010).
Liang, X. et al. Single-cell multimodal analysis reveals the dynamic immunopathogenesis of HBVaclf progression. Hepatology 80, S481 (2024).
Fu, J. et al. Impairment of CD4+ cytotoxic T cells predicts poor survival and high recurrence rates in patients with hepatocellular carcinoma. Hepatology 58, 139–149 (2013).
Homma, S. et al. Antitumour activity mediated by CD4+ cytotoxic T lymphocytes against MHC class II-negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin-12. Immunology 115, 451–461 (2005).
Muraro, E. et al. Fighting viral infections and virus-driven tumors with cytotoxic CD4(+) T cells. Front. Immunol. 8, 197 (2017).
Deeks, S. G. et al. Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021. Nat. Med. 27, 2085–2098 (2021).
Tabler, C. O. et al. CD4+ memory stem cells are infected by HIV-1 in a manner regulated in part by SAMHD1 expression. J. Virol. 88, 4976–4986 (2014).
Chen, J. et al. The reservoir of latent HIV. Front. Cell Infect. Microbiol. 12, 945956 (2022).
Kruize, Z. & Kootstra, N. A. The role of macrophages in HIV-1 persistence and pathogenesis. Front. Microbiol. 10, 2828 (2019).
Board, N. L. et al. Engaging innate immunity in HIV-1 cure strategies. Nat. Rev. Immunol. 22, 499–512 (2022).
Papin, L. et al. The autophagy nucleation factor ATG9 forms nanoclusters with the HIV-1 receptor DC-SIGN and regulates early antiviral autophagy in human dendritic cells. Int. J. Mol. Sci. 24, 9008 (2023).
Sacha, J. B. et al. Gag- and Nef-specific CD4+ T cells recognize and inhibit SIV replication in infected macrophages early after infection. Proc. Natl. Acad. Sci. USA 106, 9791–9796 (2009).
Tippalagama, R. et al. HLA-DR marks recently divided antigen-specific effector CD4 T cells in active tuberculosis patients. J. Immunol. 207, 523–533 (2021).
Lanzavecchia, A. et al. T cells can present antigens such as HIV gp120 targeted to their own surface molecules. Nature 334, 530–532 (1988).
Orentas, R. J. et al. Induction of CD4+ human cytolytic T cells specific for HIV-infected cells by a gp160 subunit vaccine. Science 248, 1234–1237 (1990).
Johnson, S. et al. Cooperativity of HIV-specific cytolytic CD4 T cells and CD8 T cells in control of HIV viremia. J. Virol. 89, 7494–7505 (2015).
Soghoian, D. Z. et al. HIV-specific cytolytic CD4 T cell responses during acute HIV infection predict disease outcome. Sci. Transl. Med. 4, 123ra125 (2012).
Dillon, S. M. et al. Granzyme B(+) CD4 T cells accumulate in the colon during chronic HIV-1 infection. Gut Microbes 14, 2045852 (2022).
Copertino, D. C., Jr. et al. The latency-reversing agent HODHBt synergizes with IL-15 to enhance cytotoxic function of HIV-specific T cells. JCI Insight. 8, e169028 (2023).
Saccon, E. et al. Cytotoxic lymphocytes target HIV-1 gag through granzyme M-mediated cleavage. Front. Immunol. 12, 669347 (2021).
Kayagaki, N. et al. Involvement of TNF-related apoptosis-inducing ligand in human CD4+ T cell-mediated cytotoxicity. J. Immunol. 162, 2639–2647 (1999).
Heinkelein, M. et al. Lysis of human immunodeficiency virus type 1 antigen-expressing cells by CD4 and CD8 T cells ex vivo. J. Infect. Dis. 174, 209–213 (1996).
Couturier, J. et al. HIV replication in conjunction with granzyme B production by CCR5+ memory CD4 T cells: Implications for bystander cell and tissue pathologies. Virology 462-463, 175–188 (2014).
Cocchi, F. et al. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 270, 1811–1815 (1995).
Saunders, K. O. et al. Secretion of MIP-1β and MIP-1α by CD8(+) T-lymphocytes correlates with HIV-1 inhibition independent of coreceptor usage. Cell Immunol. 266, 154–164 (2011).
Schieffer, M. et al. Induction of Gag-specific CD4 T cell responses during acute HIV infection is associated with improved viral control. J. Virol. 88, 7357–7366 (2014).
Douek, D. C. et al. HIV preferentially infects HIV-specific CD4+ T cells. Nature 417, 95–98 (2002).
Collora, J. A. et al. Single-cell multiomics reveals persistence of HIV-1 in expanded cytotoxic T cell clones. Immunity 55, 1013–1031.e1017 (2022).
Mickens, K. L. et al. Death and survival of gut CD4 T cells following HIV-1 infection ex vivo. PNAS Nexus 3, pgae486 (2024).
Buggert, M. et al. Limited immune surveillance in lymphoid tissue by cytolytic CD4+ T cells during health and HIV disease. PLoS Pathog. 14, e1006973 (2018).
Stanhope, P. E., Clements, M. L. & Siliciano, R. F. Human CD4+ cytolytic T lymphocyte responses to a human immunodeficiency virus type 1 gp160 subunit vaccine. J. Infect. Dis. 168, 92–100 (1993).
Stanhope, P. E. et al. An HIV-1 envelope protein vaccine elicits a functionally complex human CD4+ T cell response that includes cytolytic T lymphocytes. J. Immunol. 150, 4672–4686 (1993).
Tebas, P. et al. CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication. J. Clin. Investig. 134, e181576 (2024).
Maldini, C. R. et al. HIV-resistant and HIV-specific CAR-modified CD4(+) T cells mitigate HIV disease progression and confer CD4(+) T cell help in vivo. Mol. Ther. 28, 1585–1599 (2020).
Manfrini, N., Notarbartolo, S., Grifantini, R. & Pesce, E. SARS-CoV-2: A glance at the innate immune response elicited by infection and vaccination. Antibodies. 13, 13 (2024).
Weiss, P. & Murdoch, D. R. Clinical course and mortality risk of severe COVID-19. Lancet 395, 1014–1015 (2020).
Wong, L. R. & Perlman, S. Immune dysregulation and immunopathology induced by SARS-CoV-2 and related coronaviruses – are we our own worst enemy? Nat. Rev. Immunol. 22, 47–56 (2022).
Meckiff, B. J. et al. Imbalance of regulatory and cytotoxic SARS-CoV-2-reactive CD4(+) T cells in COVID-19. Cell 183, 1340–1353.e1316 (2020).
Bacher, P. et al. Low-avidity CD4(+) T cell responses to SARS-CoV-2 in unexposed individuals and humans with severe COVID-19. Immunity 53, 1258–1271.e1255 (2020).
Ameratunga, R. et al. Severe COVID-19 is a T cell immune dysregulatory disorder triggered by SARS-CoV-2. Expert Rev. Clin. Immunol. 18, 557–565 (2022).
Hausmann, F. et al. DISCERN: deep single-cell expression reconstruction for improved cell clustering and cell subtype and state detection. Genome Biol. 24, 212 (2023).
Hennings, V. et al. The presence of serum anti-SARS-CoV-2 IgA appears to protect primary health care workers from COVID-19. Eur. J. Immunol. 52, 800–809 (2022).
Rijkers, G. T. et al. Antigen presentation of mRNA-based and virus-vectored SARS-CoV-2 vaccines. Vaccines. 9, 848 (2021).
Nagler, A. et al. Identification of presented SARS-CoV-2 HLA class I and HLA class II peptides using HLA peptidomics. Cell Rep. 35, 109305 (2021).
Shankar-Hari, M. et al. A randomized, double-blind, placebo-controlled trial of IL-7 in critically ill COVID-19 patients. JCI Insight 10, e189150 (2025).
Kar, M. et al. CD4(+) and CD8(+) T cells are required to prevent SARS-CoV-2 persistence in the nasal compartment. Sci. Adv. 10, eadp2636 (2024).
Guy, T. et al. Granzyme K T cells and hypocomplementaemia in IgG4-RD. Pathology 57, S28 (2025).
Busnadiego, I. et al. Antiviral activity of type I, II, and III interferons counterbalances ACE2 inducibility and restricts SARS-CoV-2. mBio. 11, e01928-20 (2020).
Pavan Kumar, N. et al. Enhanced SARS-CoV-2-specific CD4+ T cell activation and multifunctionality in late convalescent COVID-19 individuals. Viruses 14, 511 (2022).
Phetsouphanh, C. et al. High titre neutralizing antibodies in response to SARS-CoV-2 infection require RBD-specific CD4 T cells that include proliferative memory cells. Front. Immunol. 13, 1032911 (2022).
Strumiliene, E. et al. Long-term pulmonary sequelae and immunological markers in patients recovering from severe and critical COVID-19 pneumonia: a comprehensive follow-up study. Medicina. 60, 1954 (2024).
Baird, S. et al. A unique cytotoxic CD4(+) T cell-signature defines critical COVID-19. Clin. Transl. Immunol. 12, e1463 (2023).
Zhu, J. et al. Machine learning of flow cytometry data reveals the delayed innate immune responses correlate with the severity of COVID-19. Front. Immunol. 14, 974343 (2023).
Li, M. et al. COVID-19 vaccine development: milestones, lessons and prospects. Signal Transduct. Target Ther. 7, 146 (2022).
Poh, X. Y. et al. Immunogenicity of mRNA vs. BBV152 vaccine boosters against Omicron subvariants: Final results from Phase B of the PRIBIVAC study, a randomized clinical trial. Vaccine 42, 126275 (2024).
Aguilar-Jimenez, W. et al. Immunogenicity of the CoronaVac vaccine in children: a real-world study. Front. Immunol. 15, 1504935 (2024).
Gardner, J. et al. Identification of cross-reactive T cell responses in adenovirus-based COVID 19 vaccines. NPJ Vaccines 9, 99 (2024).
Phan, J. M. et al. Cytotoxic T Cells Targeting spike glycoprotein are associated with hybrid immunity to SARS-CoV-2. J. Immunol. 210, 1236–1246 (2023).
Huang, R. et al. Non-spike and spike-specific memory T cell responses after the third dose of inactivated COVID-19 vaccine. Front. Immunol. 14, 1139620 (2023).
Gray-Gaillard, S. L. et al. SARS-CoV-2 inflammation durably imprints memory CD4 T cells. Sci. Immunol. 9, eadj8526 (2024).
Reeg, D. B. et al. SARS-CoV-2-specific T cell responses in immunocompromised individuals with cancer, HIV or solid organ transplants. Pathogens. 12, 244 (2023).
Augello, M. et al. Association between SARS-CoV-2 RNAemia, skewed T cell responses, inflammation, and severity in hospitalized COVID-19 people living with HIV. iScience 27, 108673 (2024).
Enssle, J. C. et al. Cytokine-responsive T- and NK-cells portray SARS-CoV-2 vaccine-responders and infection in multiple myeloma patients. Leukemia 38, 168–180 (2024).
Gressens, S. B. et al. Anti-SARS-CoV-2 cellular response after 2 and 3 doses of BNT162b2 mRNA vaccine in lymphoma patients receiving anti-CD20 antibodies. Vaccine 41, 1550–1553 (2023).
Casado-Fernández, G. et al. Pre-existing cell populations with cytotoxic activity against SARS-CoV-2 in people with HIV and normal CD4/CD8 ratio previously unexposed to the virus. Front. Immunol. 15, 1362621 (2024).
López-Cortés, L. F. et al. Humoral and cellular immunity to SARS-COV-2 after vaccination with mRNA vaccines in PLWH with discordant immune response. Influence of the vaccine administered. Front Immunol. 14, 1129753 (2023).
Guerreiro, M. et al. Adoptive transfer of ex vivo expanded SARS-CoV-2-specific cytotoxic lymphocytes: A viable strategy for COVID-19 immunosuppressed patients? Transpl. Infect. Dis. 23, e13602 (2021).
Chu, Y. et al. Manufacture and characterization of good manufacturing practice-compliant SARS-COV-2 cytotoxic T lymphocytes. J. Infect. Dis. 227, 788–799 (2023).
Crow, M. K. Pathogenesis of systemic lupus erythematosus: risks, mechanisms and therapeutic targets. Ann. Rheum. Dis. 82, 999–1014 (2023).
Porsch, F. & Binder, C. J. Autoimmune diseases and atherosclerotic cardiovascular disease. Nat. Rev. Cardiol. 21, 780–807 (2024).
Tsokos, G. C. Systemic lupus erythematosus. N. Engl. J. Med. 365, 2110–2121 (2011).
Tenbrock, K. & Rauen, T. T cell dysregulation in SLE. Clin. Immunol. 239, 109031 (2022).
Biswas, S., Bieber, K. & Manz, R. A. IL-10 revisited in systemic lupus erythematosus. Front. Immunol. 13, 970906 (2022).
al-Janadi, M. et al. Interleukin-10 (IL-10) secretion in systemic lupus erythematosus and rheumatoid arthritis: IL-10-dependent CD4+CD45RO+ T cell-B cell antibody synthesis. J. Clin. Immunol. 16, 198–207 (1996).
Houssiau, F. A. et al. Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity. Lupus. 4, 393–395 (1995).
Perez, R. K. et al. Single-cell RNA-seq reveals cell type-specific molecular and genetic associations to lupus. Science 376, eabf1970 (2022).
Puliaev, R. et al. CTL-promoting effects of CD40 stimulation outweigh B cell-stimulatory effects resulting in B cell elimination and disease improvement in a murine model of lupus. J. Immunol. 181, 47–61 (2008).
Chen, P. M. & Tsokos, G. C. The role of CD8+ T-cell systemic lupus erythematosus pathogenesis: an update. Curr. Opin. Rheumatol. 33, 586–591 (2021).
Yuan, S. et al. Phenotypical changes and clinical significance of CD4(+)/CD8(+) T cells in SLE. Lupus Sci. Med. 9, e000660 (2022).
Wang, L. et al. IL-10 enhances CTL-mediated tumor rejection by inhibiting highly suppressive CD4(+) T cells and promoting CTL persistence in a murine model of plasmacytoma. Oncoimmunology 4, e1014232 (2015).
Rupanagudi, K. V. et al. Cathepsin S inhibition suppresses systemic lupus erythematosus and lupus nephritis because cathepsin S is essential for MHC class II-mediated CD4 T cell and B cell priming. Ann. Rheum. Dis. 74, 452–463 (2015).
Giles, J. R., Kashgarian, M., Koni, P. A. & Shlomchik, M. J. B Cell-specific MHC class II deletion reveals multiple nonredundant roles for B cell antigen presentation in murine lupus. J. Immunol. 195, 2571–2579 (2015).
Hagberg, N. et al. The STAT4 SLE risk allele rs7574865[T] is associated with increased IL-12-induced IFN-γ production in T cells from patients with SLE. Ann. Rheum. Dis. 77, 1070–1077 (2018).
Hatano, R. et al. An abnormal increase in CD26(-)CD28(-) cytotoxic effector CD4 and CD8 T cell populations in patients with systemic lupus erythematosus. Int. Immunol. 37, 153–172 (2025).
Baragetti, A. et al. Disease trends over time and CD4(+)CCR5(+) T-cells expansion predict carotid atherosclerosis development in patients with systemic lupus erythematosus. Nutr. Metab. Cardiovasc Dis. 28, 53–63 (2018).
Seki, N. et al. Cytotoxic Tph subset with low B-cell helper functions and its involvement in systemic lupus erythematosus. Commun. Biol. 7, 277 (2024).
Clement, M. et al. CD4+CXCR3+ T cells and plasmacytoid dendritic cells drive accelerated atherosclerosis associated with systemic lupus erythematosus. J. Autoimmun. 63, 59–67 (2015).
Yang, M. et al. An enhanced expression level of CXCR3 on Tfh-like cells from lupus skin lesions rather than lupus peripheral blood. Clin. Immunol. 226, 108717 (2021).
Yoshimoto, S. et al. Elevated levels of fractalkine expression and accumulation of CD16+ monocytes in glomeruli of active lupus nephritis. Am. J. Kidney Dis. 50, 47–58 (2007).
Kozłowska, A., Hrycaj, P., Łącki, J. K. & Jagodziński, P. P. Perforin level in CD4+ T cells from patients with systemic lupus erythematosus. Rheumatol. Int. 30, 1627–1633 (2010).
Kosmaczewska, A. et al. CD4(+)CD28(null) T cells are expanded in moderately active systemic lupus erythematosus and secrete pro-inflammatory interferon gamma, depending on the Disease Activity Index. Lupus 29, 705–714 (2020).
Zhang, T. et al. Excessive IL-15 promotes cytotoxic CD4+ CD28– T cell-mediated renal injury in lupus nephritis. Immun. Ageing 19, 50 (2022).
Maehara, T. et al. Cytotoxic CD4+ T lymphocytes may induce endothelial cell apoptosis in systemic sclerosis. J. Clin. Investig. 130, 2451–2464 (2020).
Goto, M. et al. Age-associated CD4(+) T cells with B cell-promoting functions are regulated by ZEB2 in autoimmunity. Sci. Immunol. 9, eadk1643 (2024).
Piantoni, S. et al. A prospective study of vitamin d effects on T cells phenotype in patients with systemic lupus erythematosus treated with different regimens of supplementation for two years. Arthritis Rheumatol. 10, S724 (2014).
Comte, D. et al. Signaling lymphocytic activation molecule family member 7 engagement restores defective effector CD8+ T cell function in systemic lupus erythematosus. Arthritis Rheumatol. 69, 1035–1044 (2017).
Mezzetti, E. et al. Autoimmune heart disease: a comprehensive summary for forensic practice. Medicina. 59, 1364 (2023).
Nishimura, K. et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann. Intern. Med. 146, 797–808 (2007).
van der Woude, D. et al. Gene-environment interaction influences the reactivity of autoantibodies to citrullinated antigens in rheumatoid arthritis. Nat. Genet. 42, 814–816 (2010). author reply 816.
Wigerblad, G. et al. Autoantibodies to citrullinated proteins induce joint pain independent of inflammation via a chemokine-dependent mechanism. Ann. Rheum. Dis. 75, 730–738 (2016).
Krishnamurthy, A. et al. Identification of a novel chemokine-dependent molecular mechanism underlying rheumatoid arthritis-associated autoantibody-mediated bone loss. Ann. Rheum. Dis. 75, 721–729 (2016).
Raychaudhuri, S. et al. Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis. Nat. Genet. 44, 291–296 (2012).
Namekawa, T., Wagner, U. G., Goronzy, J. J. & Weyand, C. M. Functional subsets of CD4 T cells in rheumatoid synovitis. Arthritis Rheum. 41, 2108–2116 (1998).
Fonseka, C. Y. et al. Mixed-effects association of single cells identifies an expanded effector CD4+ T cell subset in rheumatoid arthritis. Sci. Transl. Med. 10, eaaq0305 (2018).
Chemin, K. et al. EOMES-positive CD4(+) T cells are increased in PTPN22 (1858T) risk allele carriers. Eur. J. Immunol. 48, 655–669 (2018).
Romero, V. et al. Immune-mediated pore-forming pathways induce cellular hypercitrullination and generate citrullinated autoantigens in rheumatoid arthritis. Sci. Transl. Med. 5, 209ra150 (2013).
Santiago, L. et al. Granzyme A contributes to inflammatory arthritis in mice through stimulation of osteoclastogenesis. Arthritis Rheumatol. 69, 320–334 (2017).
Khullar, A. et al. Rheumatoid arthritis synovial fluid shows enrichment of T-cells producing GMCSF which are polyfunctional for TNFα and IFNγ. Clin. Exp. Rheumatol. 42, 1435–1441 (2024).
Warrington, K. J., Takemura, S., Goronzy, J. J. & Weyand, C. M. CD4+,CD28– T cells in rheumatoid arthritis patients combine features of the innate and adaptive immune systems. Arthritis Rheum. 44, 13–20 (2001).
Bhattacharya, G. et al. IL-21/23 axis modulates inflammatory cytokines and RANKL expression in RA CD4(+) T cells via p-Akt1 signaling. Front. Immunol. 14, 1235514 (2023).
Ruschen, S., Lemm, G. & Warnatz, H. Interleukin-2 secretion by synovial fluid lymphocytes in rheumatoid arthritis. Br. J. Rheumatol. 27, 350–356 (1988).
Thurkow, E. W. et al. Increased expression of IL-15 in the synovium of patients with rheumatoid arthritis compared with patients with Yersinia-induced arthritis and osteoarthritis. J. Pathol. 181, 444–450 (1997).
Jung, H. W., Choi, S. W., Choi, J. I. & Kwon, B. S. Serum concentrations of soluble 4-1BB and 4-1BB ligand correlated with the disease severity in rheumatoid arthritis. Exp. Mol. Med. 36, 13–22 (2004).
Lacaud, M. et al. SLAMF4 orchestrates the cytotoxic response of CD4+ T cells in rheumatoid arthritis. Arthritis Rheumatol. 77, 827–841 (2025).
Akiyama, M. et al. CX3CR1(+) age-associated CD4(+) T cells contribute to synovial inflammation in late-onset rheumatoid arthritis. Inflamm. Regen. 45, 4 (2025).
Zeng, X. et al. Cytotoxic T lymphocytes expressing GPR56 are up-regulated in the peripheral blood of patients with active rheumatoid arthritis and reflect disease progression. Immunol. Investig. 51, 1804–1819 (2022).
Sanghavi, N. et al. Cardiovascular manifestations in rheumatoid arthritis. Cardiol. Rev. 32, 146–152 (2024).
Bryl, E. et al. Modulation of CD28 expression with anti-tumor necrosis factor alpha therapy in rheumatoid arthritis. Arthritis Rheum. 52, 2996–3003 (2005).
Gerli, R. et al. CD4+CD28– T lymphocytes contribute to early atherosclerotic damage in rheumatoid arthritis patients. Circulation 109, 2744–2748 (2004).
Giles, J. T. et al. Myocardial citrullination in rheumatoid arthritis: a correlative histopathologic study. Arthritis Res. Ther. 14, R39 (2012).
Scarsi, M., Ziglioli, T. & Airo, P. Baseline numbers of circulating CD28-negative T cells may predict clinical response to abatacept in patients with rheumatoid arthritis. J. Rheumatol. 38, 2105–2111 (2011).
Parameswaran, N. & Patial, S. Tumor necrosis factor-α signaling in macrophages. Crit. Rev. Eukaryot. Gene Expr. 20, 87–103 (2010).
Olofsson, T. et al. Predictors of work disability after start of anti-TNF therapy in a national cohort of Swedish patients with rheumatoid arthritis: does early anti-TNF therapy bring patients back to work? Ann. Rheum. Dis. 76, 1245–1252 (2017).
Tanaka, Y. et al. Efficacy and safety of E6011, an anti-fractalkine monoclonal antibody, in patients with active rheumatoid arthritis with inadequate response to methotrexate: results of a randomized, double-blind, placebo-controlled phase II study. Arthritis Rheumatol. 73, 587–595 (2021).
Hegarty, L. M., Jones, G. R. & Bain, C. C. Macrophages in intestinal homeostasis and inflammatory bowel disease. Nat. Rev. Gastroenterol. Hepatol. 20, 538–553 (2023).
Gomez-Bris, R. et al. CD4 T-cell subsets and the pathophysiology of Inflammatory Bowel Disease. Int. J. Mol. Sci. 24, 2696 (2023).
Vieujean, S. et al. Understanding the therapeutic toolkit for inflammatory bowel disease. Nat. Rev. Gastroenterol. Hepatol. 22, 371–394 (2025).
Shijing, Z. et al. Molecular characteristic of immune cells in ulcerative colitis patients with spleen deficiency and dampness syndrome based on single-cell RNA sequencing. [Chinese]. Chin. J. Tissue Eng. Res. 27(33), 5357–5362 (2023).
Hackstein, C. P. et al. A conserved population of MHC II-restricted, innate-like, commensal-reactive T cells in the gut of humans and mice. Nat. Commun. 13, 7472 (2022).
Medina, T. S. et al. The chromatin and single-cell transcriptional landscapes of CD4 T cells in inflammatory bowel disease link risk loci with a proinflammatory Th17 cell population. Front. Immunol. 14, 1161901 (2023).
Kottoor, S. H. et al. Microbiota-responsive cytotoxic, polyfunctional CD4 T cells are enriched in ulcerative colitis and are associated with resistance to anti-cytokine therapies. Gastroenterology 162, S-191 (2022).
London, M. et al. Stepwise chromatin and transcriptional acquisition of an intraepithelial lymphocyte program. Nat. Immunol. 22, 449–459 (2021).
Freeborn, R. A., Strubbe, S. & Roncarolo, M. G. Type 1 regulatory T cell-mediated tolerance in health and disease. Front. Immunol. 13, 1032575 (2022).
Sarrabayrouse, G. et al. CD4CD8αα lymphocytes, a novel human regulatory T cell subset induced by colonic bacteria and deficient in patients with inflammatory bowel disease. PLoS Biol. 12, e1001833 (2014).
Bousbaine, D. et al. A conserved Bacteroidetes antigen induces anti-inflammatory intestinal T lymphocytes. Science 377, 660–666 (2022).
Hatano, R. et al. Antigen presentation by small intestinal epithelial cells uniquely enhances IFN-γ secretion from CD4+ intestinal intraepithelial lymphocytes. Biochem. Biophys. Res. Commun. 435, 592–596 (2013).
Bilate, A. M. et al. T Cell receptor is required for differentiation, but not maintenance, of intestinal CD4(+) intraepithelial lymphocytes. Immunity 53, 1001–1014.e1020 (2020).
Olivares-Villagómez, D. & Van Kaer, L. TL and CD8αα: enigmatic partners in mucosal immunity. Immunol. Lett. 134, 1–6 (2010).
Ivanov, I. I. et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 139, 485–498 (2009).
Atarashi, K. et al. Induction of colonic regulatory T cells by indigenous Clostridium species. Science 331, 337–341 (2011).
Zhou, C., Qiu, Y. & Yang, H. CD4CD8αα IELs: they have something to say. Front. Immunol. 10, 2269 (2019).
Martini, G. R. et al. Selection of cross-reactive T cells by commensal and food-derived yeasts drives cytotoxic T(H)1 cell responses in Crohn’s disease. Nat. Med. 29, 2602–2614 (2023).
Mucida, D. et al. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science 317, 256–260 (2007).
Das, G. et al. An important regulatory role for CD4+CD8 alpha alpha T cells in the intestinal epithelial layer in the prevention of inflammatory bowel disease. Proc. Natl. Acad. Sci. USA 100, 5324–5329 (2003).
Meresse, B. et al. Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease. Immunity 21, 357–366 (2004).
Bonhagen, K. et al. Cytotoxic reactivity of gut lamina propria CD4+ alpha beta T cells in SCID mice with colitis. Eur. J. Immunol. 26, 3074–3083 (1996).
DePaolo, R. W. et al. Co-adjuvant effects of retinoic acid and IL-15 induce inflammatory immunity to dietary antigens. Nature 471, 220–224 (2011).
Li, C., Prakhar, P. & Park, J. H. The homeostatic γc cytokines IL-7 and IL-15 suppress the induction of CD4(+)CD8αα(+) intraepithelial T cells in the gut. Cell Mol. Immunol. 19, 751–753 (2022).
Forsberg, G., Hernell, O., Hammarström, S. & Hammarström, M. L. Concomitant increase of IL-10 and pro-inflammatory cytokines in intraepithelial lymphocyte subsets in celiac disease. Int. Immunol. 19, 993–1001 (2007).
Costes, L. M. M. et al. IL-10 signaling prevents gluten-dependent intraepithelial CD4(+) cytotoxic T lymphocyte infiltration and epithelial damage in the small intestine. Mucosal Immunol. 12, 479–490 (2019).
Sasahara, T., Tamauchi, H., Ikewaki, N. & Kubota, K. Unique properties of a cytotoxic CD4+CD8+ intraepithelial T-cell line established from the mouse intestinal epithelium. Microbiol. Immunol. 38, 191–199 (1994).
Park, S. et al. Granzyme A-producing CD4 T cells are drivers of immune checkpoint blockade-induced colitis. Inflamm. Bowel Dis. 30, S59–S60 (2024).
Shi, Y. et al. Gut microbiota in treating inflammatory digestive diseases: Current challenges and therapeutic opportunities. Imeta. 4, e265 (2025).
Imamura, E. et al. Anti-IL-23 receptor monoclonal antibody prevents CD4(+) T cell-mediated colitis in association with decreased systemic Th1 and Th17 responses. Eur. J. Pharm. 824, 163–169 (2018).
Wang, J. et al. Novel bispecific nanobody mitigates experimental intestinal inflammation in mice by targeting TNF-α and IL-23p19 bioactivities. Clin. Transl. Med. 14, e1636 (2024).
Ma, K. et al. Combinations of anti-GITR antibody and CD28 superagonist ameliorated dextran sodium sulfate-induced mouse colitis. Clin. Exp. Immunol. 208, 340–350 (2022).
Gaziano, T. A. et al. Growing epidemic of coronary heart disease in low- and middle-income countries. Curr. Probl. Cardiol. 35, 72–115 (2010).
Libby, P., Lichtman, A. H. & Hansson, G. K. Immune effector mechanisms implicated in atherosclerosis: from mice to humans. Immunity 38, 1092–1104 (2013).
Medina-Leyte, D. J. et al. Endothelial dysfunction, inflammation and coronary artery disease: potential biomarkers and promising therapeutical approaches. Int. J. Mol. Sci. 22, 3850 (2021).
Jinnouchi, H. et al. Diversity of macrophage phenotypes and responses in atherosclerosis. Cell Mol. Life Sci. 77, 1919–1932 (2020).
Xu, H. et al. Vascular macrophages in atherosclerosis. J. Immunol. Res. 2019, 4354786 (2019).
Wolf, D. & Ley, K. ImmuNity And Inflammation In Atherosclerosis. Circ. Res. 124, 315–327 (2019).
Weinstock, A. et al. Wnt signaling enhances macrophage responses to IL-4 and promotes resolution of atherosclerosis. Elife. 10, e67932 (2021).
Ou, H. X. et al. Regulatory T cells as a new therapeutic target for atherosclerosis. Acta Pharm. Sin. 39, 1249–1258 (2018).
Tekguc, M. et al. Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells. Proc. Natl. Acad. Sci. USA. 118, e2023739118 (2021).
Vallejo, J., Cochain, C., Zernecke, A. & Ley, K. Heterogeneity of immune cells in human atherosclerosis revealed by scRNA-Seq. Cardiovasc Res. 117, 2537–2543 (2021).
Liuzzo, G. et al. Unusual CD4+CD28null T lymphocytes and recurrence of acute coronary events. J. Am. Coll. Cardiol. 50, 1450–1458 (2007).
Chowdhury, R. R. et al. Human coronary plaque T cells are clonal and cross-react to virus and self. Circ. Res. 130, 1510–1530 (2022).
Liuzzo, G. et al. Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes. Circulation 101, 2883–2888 (2000).
Zal, B. et al. Heat-shock protein 60-reactive CD4+CD28null T cells in patients with acute coronary syndromes. Circulation 109, 1230–1235 (2004).
Yadav, A. K., Kumar, V. & Jha, V. Heat shock proteins 60 and 70 specific proinflammatory and cytotoxic response of CD4+CD28null cells in chronic kidney disease. Mediators Inflamm. 2013, 384807 (2013).
Winkels, H. & Wolf, D. Heterogeneity of T cells in atherosclerosis defined by single-cell RNA-sequencing and cytometry by time of flight. Arterioscler. Thromb. Vasc. Biol. 41, 549–563 (2021).
Depuydt, M. et al. Granzyme B+ CD4+ T cells associate with an unstable plaque phenotype in advanced human atherosclerosis. Cardiovasc. Res. 118, i250 (2022).
Nakajima, T. et al. De novo expression of killer immunoglobulin-like receptors and signaling proteins regulates the cytotoxic function of CD4 T cells in acute coronary syndromes. Circ. Res. 93, 106–113 (2003).
Lezama, D., Iqbal, A. & Dumitriu, I. BS60 characterisation of chemokine receptors in CD4+CD28NULL T lymphocytes from patients with acute coronary syndrome. Heart 109, A289–A289 (2023).
Zhang, X. et al. Interleukin 12 induces T-cell recruitment into the atherosclerotic plaque. Circ. Res. 98, 524–531 (2006).
Kitamura, K. et al. P-Selectin glycoprotein ligand-1 (PSGL-1) expressing CD4 T cells contribute plaque instability in acute coronary syndrome. Circ. J. 82, 2128–2135 (2018).
Samstag, Y. et al. Reactive oxidative species-modulated Ca(2+) release regulates β(2) integrin activation on CD4(+) CD28(null) T Cells of acute coronary syndrome patients. J. Immunol. 205, 2276–2286 (2020).
Pryshchep, S., Sato, K., Goronzy, J. J. & Weyand, C. M. T cell recognition and killing of vascular smooth muscle cells in acute coronary syndrome. Circ. Res. 98, 1168–1176 (2006).
Lee, L. Y. et al. Interferon-γ impairs human coronary artery endothelial glucose metabolism by tryptophan catabolism and activates fatty acid oxidation. Circulation 144, 1612–1628 (2021).
Dumitriu, I. E., Bullenkamp, J., Chhetri, I. & Kaski, J. C. The expansion of pro-inflammatory CD41CD28null T lymphocytes inmyocardial infarction is driven by homeostatic cytokines interleukin-7 (IL-7) and IL-15 and not by inflammatory cytokines. Cardiovasc Res. 114, S70–S71 (2018).
Li, Y. et al. CD4+ natural killer T cells potently augment aortic root atherosclerosis by perforin- and granzyme B-dependent cytotoxicity. Circ. Res. 116, 245–254 (2015).
Bullenkamp, J. et al. Interleukin-7 and interleukin-15 drive CD4+CD28null T lymphocyte expansion and function in patients with acute coronary syndrome. Cardiovasc. Res. 117, 1935–1948 (2021).
Nakajima, T. et al. T-cell-mediated lysis of endothelial cells in acute coronary syndromes. Circulation 105, 570–575 (2002).
Sato, K. et al. TRAIL-expressing T cells induce apoptosis of vascular smooth muscle cells in the atherosclerotic plaque. J. Exp. Med. 203, 239–250 (2006).
Tomas, L. et al. Low levels of CD4(+)CD28(null) T cells at baseline are associated with first-time coronary events in a prospective population-based case-control cohort. Arterioscler. Thromb. Vasc. Biol. 40, 426–436 (2020).
Xiong, J. et al. Bulk and single-cell characterisation of the immune heterogeneity of atherosclerosis identifies novel targets for immunotherapy. BMC Biol. 21, 46 (2023).
Ruggio, A. et al. Correlation between CD4(+)CD28(null) T lymphocytes, regulatory T cells and plaque rupture: an optical coherence tomography study in acute coronary syndromes. Int J. Cardiol. 276, 289–292 (2019).
Rizzello, V. et al. Modulation of CD4(+)CD28(null) T lymphocytes by tumor necrosis factor-alpha blockade in patients with unstable angina. Circulation 113, 2272–2277 (2006).
Sato, K. et al. Statins reduce endothelial cell apoptosis via inhibition of TRAIL expression on activated CD4 T cells in acute coronary syndrome. Atherosclerosis 213, 33–39 (2010).
Rammos, G. & Kondomerkos, D. The role of CD4+CD28(null) T-lymphocytes and statins in rheumatoid arthritis and unstable atherosclerotic plaque. Hellenic J. Cardiol. 48, 165–174 (2007).
Link, A. et al. Rosuvastatin induces apoptosis in CD4(+)CD28 (null) T cells in patients with acute coronary syndromes. Clin. Res Cardiol. 100, 147–158 (2011).
Xu, R. et al. Kv1.3 channels as a potential target for immunomodulation of CD4+ CD28null T cells in patients with acute coronary syndrome. Clin. Immunol. 142, 209–217 (2012).
Takahashi, Y. et al. Histological validation of atrial structural remodelling in patients with atrial fibrillation. Eur. Heart J. 44, 3339–3353 (2023).
Iwasaki, Y.-K, Nishida, K., Kato, T. & Nattel, S. Atrial fibrillation pathophysiology: implications for management. Circulation 124, 2264–2274 (2011).
Kim, P., Chu, N., Davis, J. & Kim, D. H. Mechanoregulation of myofibroblast fate and cardiac fibrosis. Adv. Biosyst. 2, 1700172 (2018).
Wynn, T. A. & Ramalingam, T. R. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat. Med 18, 1028–1040 (2012).
Zaidi, Y. et al. Immune regulation of cardiac fibrosis post myocardial infarction. Cell Signal 77, 109837 (2021).
Bai, W., Liu, Z. Q. & He, P. Y. & Muhuyati. The role of IL-6, IL-10, TNF-α and PD-1 expression on CD4 T cells in atrial fibrillation. Heliyon 9, e18818 (2023).
Dumitriu, I. E. et al. P511Deregulations in CD4+ T lymphocytes subsets promote inflammation in atrial fibrillation. Cardiovasc. Res. 114, S124–S124 (2018).
Hammer, A., Niessner, A. & Sulzgruber, P. The impact of CD4(+)CD28(null) T lymphocytes on atrial fibrillation: a potential pathophysiological pathway. Inflamm. Res. 70, 1011–1014 (2021).
Guo, Y., Lip, G. Y. & Apostolakis, S. Inflammation in atrial fibrillation. J. Am. Coll. Cardiol. 60, 2263–2270 (2012).
Liu, Y., Shi, Q., Ma, Y. & Liu, Q. The role of immune cells in atrial fibrillation. J. Mol. Cell Cardiol. 123, 198–208 (2018).
Sulzgruber, P. et al. The impact of CD4(+)CD28(null) T-lymphocytes on atrial fibrillation and mortality in patients with chronic heart failure. Thromb. Haemost. 117, 349–356 (2017).
Park, D. Y. et al. Incidence and risk factors of atrial fibrillation and atrial arrhythmias in people living with HIV: a systematic review and meta-analysis. J. Int. Card. Electrophysiol. 65, 183–191 (2022).
Xiang, J. et al. Bioinformatics analysis reveals the potential common genes and immune characteristics between atrial fibrillation and periodontitis. J. Periodontal. Res. 59, 104–118 (2024).
González-Osuna, L. et al. Senescent CD4(+)CD28(-) T lymphocytes as a potential driver of Th17/Treg imbalance and alveolar bone resorption during periodontitis. Int. J. Mol. Sci. 23, 2543 (2022).
Oliveri, F. et al. Statin and postcardiac surgery atrial fibrillation prevention: a systematic review and meta-analysis. J. Cardiovasc. Pharm. 80, 180–186 (2022).
Pastori, D. et al. Statin use and mortality in atrial fibrillation: a systematic review and meta-analysis of 100,287 patients. Pharm. Res. 165, 105418 (2021).
Ciofalo, A. et al. Giant Cell Arteritis (GCA): Pathogenesis, clinical aspects and treatment approaches. Curr. Rheumatol. Rev. 15, 259–268 (2019).
Bilton, E. J. & Mollan, S. P. Giant cell arteritis: reviewing the advancing diagnostics and management. Eye 37, 2365–2373 (2023).
Deng, J. et al. Toll-like receptors 4 and 5 induce distinct types of vasculitis. Circ. Res. 104, 488–495 (2009).
Salvarani, C., Pipitone, N., Versari, A. & Hunder, G. G. Clinical features of polymyalgia rheumatica and giant cell arteritis. Nat. Rev. Rheumatol. 8, 509–521 (2012).
Weyand, C. M. et al. Cytokines, growth factors and proteases in medium and large vessel vasculitis. Clin. Immunol. 206, 33–41 (2019).
Samson, M. et al. Improvement of Treg immune response after treatment with tocilizumab in giant cell arteritis. Clin. Transl. Immunol. 10, e1332 (2021).
de Menthon, M. et al. Excessive interleukin-15 transpresentation endows NKG2D+CD4+ T cells with innate-like capacity to lyse vascular endothelium in granulomatosis with polyangiitis (Wegener’s). Arthritis Rheum. 63, 2116–2126 (2011).
Moosig, F., Csernok, E., Wang, G. & Gross, W. L. Costimulatory molecules in Wegener’s granulomatosis (WG): lack of expression of CD28 and preferential up-regulation of its ligands B7-1 (CD80) and B7-2 (CD86) on T cells. Clin. Exp. Immunol. 114, 113–118 (1998).
Zhang, H. et al. CD28 signaling controls metabolic fitness of pathogenic T cells in medium and large vessel vasculitis. J. Am. Coll. Cardiol. 73, 1811–1823 (2019).
Carmona, E. G. et al. Single-cell transcriptomic profiling reveals a pathogenic role of cytotoxic CD4(+) T cells in giant cell arteritis. J. Autoimmun. 142, 103124 (2024).
Mohan, S. V. et al. Giant cell arteritis: immune and vascular aging as disease risk factors. Arthritis Res. Ther. 13, 231 (2011).
Corbera-Bellalta, M. et al. Blocking interferon γ reduces expression of chemokines CXCL9, CXCL10 and CXCL11 and decreases macrophage infiltration in ex vivo cultured arteries from patients with giant cell arteritis. Ann. Rheum. Dis. 75, 1177–1186 (2016).
Terrier, B. et al. Interleukin-21 modulates Th1 and Th17 responses in giant cell arteritis. Arthritis Rheum. 64, 2001–2011 (2012).
Heidenreich, P. A. et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J. Am. Coll. Cardiol. 79, 1757–1780 (2022).
Shah, K. S., Kittleson, M. M. & Kobashigawa, J. A. Updates on heart transplantation. Curr. Heart Fail Rep. 16, 150–156 (2019).
Stewart, S. et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J. Heart Lung Transpl. 24, 1710–1720 (2005).
Benzimra, M., Calligaro, G. L. & Glanville, A. R. Acute rejection. J. Thorac. Dis. 9, 5440–5457 (2017).
Manfredini, V., Leone, O., Agostini, V. & Potena, L. Antibody-mediated rejection in heart transplantation: new developments and old uncertainties. Curr. Opin. Organ. Transpl. 22, 207–214 (2017).
Costello, J. P., Mohanakumar, T. & Nath, D. S. Mechanisms of chronic cardiac allograft rejection. Tex. Heart Inst. J. 40, 395–399 (2013).
Short, S., Lewik, G. & Issa, F. An immune atlas of T cells in transplant rejection: pathways and therapeutic opportunities. Transplantation 107, 2341–2352 (2023).
Chen, Y. & Wood, K. J. Interleukin-23 and TH17 cells in transplantation immunity: does 23+17 equal rejection? Transplantation 84, 1071–1074 (2007).
Huang, D. L. et al. The immunomodulation role of Th17 and Treg in renal transplantation. Front. Immunol. 14, 1113560 (2023).
Liu, Z., Fan, H. & Jiang, S. CD4(+) T-cell subsets in transplantation. Immunol. Rev. 252, 183–191 (2013).
Roberto, A. et al. Role of naive-derived T memory stem cells in T-cell reconstitution following allogeneic transplantation. Blood 125, 2855–2864 (2015).
Zou, D. et al. CD4+ T cell immunity is dependent on an intrinsic stem-like program. Nat. Immunol. 25, 66–76 (2024).
Zou, D. et al. Identification of molecular determinants that govern the self-renewal and effector differentiation potential of stem-like CD4+ effector precursors. Am. J. Transpl. 23, S768–S768 (2023).
van Emmerik, N. E. et al. The avidity, not the mere presence, of primed cytotoxic T-lymphocytes for donor human leukocyte class II antigens determines their clinical relevance after heart transplantation. J. Heart Lung Transpl. 16, 240–249 (1997).
Pietra, B. A. et al. CD4 T cell-mediated cardiac allograft rejection requires donor but not host MHC class II. J. Clin. Investig. 106, 1003–1010 (2000).
Boix, F. et al. Pretransplant CD28 biomarker (levels of expression and quantification of molecules per cell) in peripheral CD4(+) T cells predicts acute rejection episodes in liver and kidney recipients. Transpl. Proc. 48, 2987–2989 (2016).
Giaretta, F. et al. Different regulatory and cytotoxic CD4+ T lymphocyte profiles in renal transplants with antibody-mediated chronic rejection or long-term good graft function. Transpl. Immunol. 28, 48–56 (2013).
Zhang, W. et al. Single-cell profiling of peripheral blood mononuclear cell identifies immune populations associated with high risk of early acute rejection. J. Am. Soc. Nephrol. 31, 28 (2020).
Brugière, O. et al. Chronic lung allograft dysfunction is associated with an early increase of circulating cytotoxic CD4+CD57+ILT2+ T cells, selectively inhibited by the immune check-point HLA-G. J. Heart Lung Transpl. 41, 626–640 (2022).
Popescu, I. et al. Persistence of increased type-1 alloeffector CD4+ T cell responses from ACR into CLAD in lung transplant recipients. J. Heart Lung Transpl. 39, S165–S165 (2020).
Moghbeli, K. et al. Molecular drivers of tissue-resident memory T cell formation in lung allografts. J. Heart Lung Transpl. 42, S26–S26 (2023).
Kwok, C. et al. Necroptosis is involved in CD4+ T cell-mediated microvascular endothelial cell death and chronic cardiac allograft rejection. Transplantation 101, 2026–2037 (2017).
Grazia, T. J. et al. Acute cardiac allograft rejection by directly cytotoxic CD4 T cells: parallel requirements for Fas and perforin. Transplantation 89, 33–39 (2010).
Van Laecke, S., Malfait, T., Schepers, E. & Van Biesen, W. Cardiovascular disease after transplantation: an emerging role of the immune system. Transpl. Int. 31, 689–699 (2018).
Koike, N. et al. Effects of adding P38 mitogen-activated protein-kinase inhibitor to celsior solution in canine heart transplantation from non-heart-beating donors. Transplantation 77, 286–292 (2004).
Zhang, X., Cao, Y., Meng, A. & Bai, Y. Graft expression of p38 and tumor necrosis factor-alpha in heart transplantation in rats. Prog. Transpl. 12, 309–313 (2002).
Dedeoglu, B. et al. CD4(+) CD28(null) T cells are not alloreactive unless stimulated by interleukin-15. Am. J. Transpl. 18, 341–350 (2018).
Echeverría, A. et al. CD4+CD28null T lymphocytes resemble CD8+CD28null T lymphocytes in their responses to IL-15 and IL-21 in HIV-infected patients. J. Leukoc. Biol. 98, 373–384 (2015).
Kong, D. et al. The dynamic cellular landscape of grafts with acute rejection after heart transplantation. J. Heart Lung Transpl. 42, 160–172 (2023).
Yoon, S. H. et al. Selective addition of CXCR3(+) CCR4(-) CD4(+) Th1 cells enhances generation of cytotoxic T cells by dendritic cells in vitro. Exp. Mol. Med. 41, 161–170 (2009).
Potena, L., Zuckermann, A., Barberini, F. & Aliabadi-Zuckermann, A. Complications of cardiac transplantation. Curr. Cardiol. Rep. 20, 73 (2018).
Shabir, S. et al. CMV Drives Expansion of cytotoxic CD4+CD27nullCD28null T cells in renal transplant recipients, resulting in NKG2D-dependent endothelial stress, apoptosis and late graft dysfunction. Transplantation. 98, 77 (2014).
Desai, R. et al. Impact of cytomegalovirus on long-term mortality and cancer risk after organ transplantation. Transplantation 99, 1989–1994 (2015).
Vincenti, F. et al. Belatacept and long-term outcomes in kidney transplantation. N. Engl. J. Med. 374, 333–343 (2016).
Demmers, M. W. et al. Substantial proliferation of human renal tubular epithelial cell-reactive CD4+CD28null memory T cells, which is resistant to tacrolimus and everolimus. Transplantation 97, 47–55 (2014).
Ridker, P. M. et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359, 2195–2207 (2008).
Wu, Z. et al. Single-cell analysis of graft-infiltrating host cells identifies caspase-1 as a potential therapeutic target for heart transplant rejection. Front. Immunol. 14, 1251028 (2023).
Melenhorst, J. J. et al. Graft versus leukemia response without graft-versus-host disease elicited by adoptively transferred multivirus-specific T-cells. Mol. Ther. 23, 179–183 (2015).
Ott, P. A. et al. A phase Ib trial of personalized neoantigen therapy plus Anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. Cell 183, 347–362.e324 (2020).
Zhang, Z. et al. Humoral and cellular immune memory to four COVID-19 vaccines. Cell 185, 2434–2451.e2417 (2022).
Boulch, M. et al. A cross-talk between CAR T cell subsets and the tumor microenvironment is essential for sustained cytotoxic activity. Sci. Immunol. 6, eabd4344 (2021).
Hosseini, A. et al. CTLA-4: from mechanism to autoimmune therapy. Int. Immunopharmacol. 80, 106221 (2020).
Yang, X. et al. Single-cell analysis identifies distinct populations of cytotoxic CD4(+) T cells linked to the therapeutic efficacy of immune checkpoint inhibitors in metastatic renal cell carcinoma. J. Inflamm. Res. 17, 4505–4523 (2024).
Scarsi, M., Ziglioli, T. & Airò, P. Decreased circulating CD28-negative T cells in patients with rheumatoid arthritis treated with abatacept are correlated with clinical response. J. Rheumatol. 37, 911–916 (2010).
Bryl, E., Vallejo, A. N., Weyand, C. M. & Goronzy, J. J. Down-regulation of CD28 expression by TNF-alpha. J. Immunol. 167, 3231–3238 (2001).
Tani, M. et al. Generation of CD4+ cytotoxic T lymphocytes stimulated by immobilized anti-CD3 monoclonal antibody and interleukin-2 in cancer patients. Int. J. Cancer 60, 802–807 (1995).
Khan, S. et al. Interleukin inhibitors and the associated risk of candidiasis. Front. Immunol. 15, 1372693 (2024).
Fricker, L. D. Proteasome inhibitor drugs. Annu. Rev. Pharm. Toxicol. 60, 457–476 (2020).
Albarrán, V. et al. Adoptive T cell therapy for solid tumors: current landscape and future challenges. Front. Immunol. 15, 1352805 (2024).
Morotti, M. et al. Promises and challenges of adoptive T-cell therapies for solid tumours. Br. J. Cancer 124, 1759–1776 (2021).
Larson, R. C. & Maus, M. V. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat. Rev. Cancer 21, 145–161 (2021).
Bonifacius, A. et al. Rapid manufacturing of highly cytotoxic clinical-grade SARS-CoV-2-specific T cell products covering SARS-CoV-2 and its variants for adoptive T cell therapy. Front. Bioeng. Biotechnol. 10, 867042 (2022).
Vasileiou, S. et al. Allogeneic, off-the-shelf, SARS-CoV-2-specific T cells (ALVR109) for the treatment of COVID-19 in high-risk patients. Haematologica 108, 1840–1850 (2023).
Tendeiro Rego, R., Morris, E. C. & Lowdell, M. W. T-cell receptor gene-modified cells: past promises, present methodologies and future challenges. Cytotherapy 21, 341–357 (2019).
Li, J. et al. A novel costimulatory molecule gene-modified leukemia cell-derived exosome-targeted CD4(+) T cell vaccine efficiently enhances anti-leukemia immunity. Front. Immunol. 13, 1043484 (2022).
Batra, S. A. et al. Glypican-3-specific CAR T cells coexpressing IL15 and IL21 have superior expansion and antitumor activity against hepatocellular carcinoma. Cancer Immunol. Res. 8, 309–320 (2020).
Steffin, D. et al. Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers. Nature 637, 940–946 (2025).
Li, D. et al. rhIL-7-hyFc, a long-acting interleukin-7, improves efficacy of CAR-T cell therapy in solid tumors. J. Immunother. Cancer. 12, e008989 (2024).
Heller, K. N., Gurer, C. & Münz, C. Virus-specific CD4+ T cells: ready for direct attack. J. Exp. Med. 203, 805–808 (2006).
Taylor, G. S. et al. Dual stimulation of Epstein-Barr Virus (EBV)-specific CD4+– and CD8+-T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma. J. Virol. 78, 768–778 (2004).
Thomson, S. A. et al. Targeting a polyepitope protein incorporating multiple class II-restricted viral epitopes to the secretory/endocytic pathway facilitates immune recognition by CD4+ cytotoxic T lymphocytes: a novel approach to vaccine design. J. Virol. 72, 2246–2252 (1998).
Nanjundappa, R. H. et al. GP120-specific exosome-targeted T cell-based vaccine capable of stimulating DC- and CD4(+) T-independent CTL responses. Vaccine 29, 3538–3547 (2011).
Landmeier, S. et al. Gene-engineered varicella-zoster virus reactive CD4+ cytotoxic T cells exert tumor-specific effector function. Cancer Res. 67, 8335–8343 (2007).
Naghavian, R. et al. Microbial peptides activate tumour-infiltrating lymphocytes in glioblastoma. Nature 617, 807–817 (2023).
Andersen, R. S. et al. Dissection of T-cell antigen specificity in human melanoma. Cancer Res. 72, 1642–1650 (2012).
Ning, J. et al. Functional virus-specific memory T cells survey glioblastoma. Cancer Immunol. Immunother. 71, 1863–1875 (2022).
Çuburu, N. et al. Harnessing anti-cytomegalovirus immunity for local immunotherapy against solid tumors. Proc. Natl. Acad. Sci. USA 119, e2116738119 (2022).
Sefrin, J. P. et al. Sensitization of tumors for attack by virus-specific CD8+ T-cells through antibody-mediated delivery of immunogenic T-cell epitopes. Front. Immunol. 10, 1962 (2019).